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A B S T R A C T
Background
Cancer pain is an important and distressing symptom that tends to increase in frequency and intensity as the cancer advances. For
people with advanced cancer, the prevalence of pain can be as high as 90%. It has been estimated that 30% to 50% of people with
cancer categorise their pain as moderate to severe, with between 75% and 90% of people with cancer experiencing pain that they
describe as having a major impact on their daily life. Epidemiological studies suggest that approximately 15% of people with cancer
pain fail to experience acceptable pain relief with conventional management. Uncontrolled pain can lead to physical and psychological
distress and can, consequently, have a drastic effect on people’s quality of life.
Objectives
To determine the analgesic efficacy of hydromorphone in relieving cancer pain, as well as the incidence and severity of any adverse
events.
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase and clinical trials registers up to April 2016.
There were no language, document type or publication status limitations applied in the search.
Selection criteria
We included randomised controlled trials (RCTs) that compared hydromorphone with placebo or other active pain medication for
cancer pain in both adults and children. The four main outcomes selected have previously been identified as important to people with
cancer; pain no worse than mild pain, and the impact of the treatment on consciousness, appetite and thirst. We did not consider
physician-, nurse- or carer-reported measures of pain.
Data collection and analysis
Two review authors independently extracted data. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval
(CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI.
We used a random-effects model and assessed the risk of bias for all included studies. A meta-analysis was not completed on any of
the primary outcomes in this review due to the lack of data. We assessed the evidence using GRADE and created two ’Summary of
findings’ tables.
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Main results
We included four studies (604 adult participants), which compared hydromorphone to oxycodone (two studies) or morphine (two
studies). Overall, the included studies were at low or unclear risk of bias, rated unclear due to unknown status of blinding of outcome
assessment; we rated three studies at high risk of bias for potential conflict of interest. Data for 504 participants were available for
analysis. We collected data on endpoint participant-reported pain intensity measured with a visual analogue scale (VAS) (mean ±
standard deviation (SD): hydromorphone 28.86 ± 17.08, n = 19; oxycodone 30.30 ± 25.33, n = 12; scale from 0 to 100 with higher
score indicating worse pain), and Brief Pain Inventory (BPI) 24 hours worst pain subscale (mean ± SD: hydromorphone 3.5 ± 2.9,
n = 99; morphine 4.3 ± 3.0, n = 101, scale from 0 to 10 with higher score indicating worse pain). The data demonstrated a similar
effect between groups with both comparisons. The pain intensity data showed that participants in all four trials achieved no worse than
mild pain. There were several adverse events: some were the expected opioid adverse effects such as nausea, constipation and vomiting;
others were not typical opioid adverse effects (for example, decreased appetite, dizziness and pyrexia, as shown in Table 1 in the main
review), but generally showed no difference between groups. There were three deaths in the morphine group during the trial period,
considered to be due to disease progression and unrelated to the drug. Three trials had over 10% dropout, but the reason and proportion
of dropout was balanced between groups. The overall quality of evidence was very low mainly due to high risk of bias, imprecision of
effect estimates and publication bias. There were no data available for children or for several participant-important outcomes, including
participant-reported pain relief and treatment impact on consciousness, appetite or thirst.
Authors’ conclusions
This review indicated little difference between hydromorphone and other opioids in terms of analgesic efficacy. Data gathered in this
review showed that hydromorphone had a similar effect on participant-reported pain intensity as reported for oxycodone and morphine.
Participants generally achieved no worse than mild pain after taking hydromorphone, which is comparable with the other drugs. It
produced a consistent analgesic effect through the night and could be considered for use in people with cancer pain experiencing
sleep disturbance. However, the overall quality of evidence was very low mainly due to risk of bias, imprecision of effect estimates
and publication bias. This review only included four studies with limited sample size and a range of study designs. Data for some
important outcomes, such as impact of the treatment on consciousness, appetite or thirst, were not available. Therefore, we were unable
to demonstrate superiority or inferiority of hydromorphone in comparison with other analgesics for these outcomes. We recommend
that further research with larger sample sizes and more comprehensive outcome data collection is required.
P L A I N L A N G U A G E S U M M A R Y
Hydromorphone for the treatment of cancer pain
Background
Over 75% of people with cancer experience pain. Around 30% to 50% of these people have moderate to severe pain, which can have
a negative impact on daily life. Cancer pain is a distressing symptom that tends to worsen as the disease progresses. Hydromorphone
may help relieve these symptoms.
Cancer-related pain is usually treated with medicines such as morphine, oxycodone, fentanyl or hydromorphone. This review looked
at how effective hydromorphone was in relieving symptoms of moderate to severe cancer pain.
Results
In April 2016, we searched for clinical trials looking at hydromorphone in people with moderate to severe cancer pain. We found four
small, but well conducted, studies with 604 adults (none of the studies included children) comparing hydromorphone with oxycodone
or morphine.
Based on very low quality evidence, we found no differences between the treatment groups relating to pain intensity and most people
had good pain relief. Hydromorphone seemed to work as well as morphine and oxycodone. There were some side effects, such as
confusion, constipation and diarrhoea, but generally there was no difference between people taking hydromorphone and people taking
morphine or oxycodone.
Conclusions
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The studies did not provide enough high quality evidence to draw conclusions from; however, based on very low quality evidence,
hydromorphone seemed to work as well as morphine and oxycodone and had similar side effects. Hydromorphone provided consistent
pain relief through the night and could be considered for use in people with cancer who find it difficult to sleep due to the pain.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hydromorphone compared to oxycodone for cancer pain
Patient or population: people with cancer pain
Setting: unclear if these are inpat ients or community pat ients
Intervention: hydromorphone
Comparison: oxycodone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Oxycodone Hydromorphone
Participant- reported
pain intensity
Pain intensity scores:
1 study (n = 31) using VAS (0 to 100, higher = worse outcome): mean (± SD) endpoint score for
hydromorphone 28.86 ± 17.08 (n = 19); oxycodone 30.30 ± 25.33 (n = 12). SD of the oxycodone
group was much more widespread than for the hydromorphone group
1 study (n = 81) using BPI (0 to 10; higher = worse outcome): mean change score of ’pain at its
worst in the past 24 hours’ for hydromorphone -1.8 ± 3.29 (n = 40); oxycodone -1.7 ± 3.91 (n = 41)
No worse than mild pain:
1 study (n = 31) using 5-point categorical pain intensity scale (0 to 4; higher = worse outcome):
mean (± SD) score across all days for hydromorphone 1.5 ± 0.1; oxycodone 1.4 ± 0.1. Both groups
achieved no worse than mild pain
1 study (n = 81) using BPI (0 to 10; higher = worse outcome): ’average pain in the past 24 hours’
for hydromorphone 2.9; oxycodone 3.3, SD not reported. Both groups achieved no worse than mild
pain (def ined as score of ≤ 4)
⊕©©©
Very low1,2,3
For pain intensity,
the results were sim-
ilar in hydromorphone
and oxycodone groups,
although data were
skewed
Both oxycodone and
hydromorphone groups
had mean pain levels
of ’no worse than mild
pain’
Adverse events - nau-
sea
Follow-up: 28 days
See comment See comment Not est imable 254
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if
there is any dif ference
between intervent ions
Adverse events - con-
stipation
Follow-up: 28 days
See comment See comment Not est imable 254
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if
there is any dif ference
between intervent ions
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Adverse events - vom-
iting
Follow-up: 28 days
See comment See comment Not est imable 254
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if
there is any dif ference
between intervent ions
Leaving the study early
Follow-up: 14-28 days
Study population RR 0.61
(0.2 to 1.87)
304
(2 studies)
⊕©©©
Very low1,2,4
-
480 per 1000 293 per 1000
(96 to 898)
Moderate
470 per 1000 287 per 1000
(94 to 879)
Death
Follow-up: 28 days
See comment See comment Not est imable 260
(1 study)
⊕©©©
very low1,2,3
We are uncertain if
there is any dif ference
between intervent ions
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
BPI: Brief Pain Inventory; CI: conf idence interval; RR: risk rat io; SD: standard deviat ion; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded once: risk of bias: sample size of < 200 per treatment arm.
2 Downgraded once: imprecision: sample size was smaller than opt imal information size; CI around est imate of ef fect was
wide and included no ef fect and appreciable benef it / harm.
3 Downgraded once: publicat ion bias: only 1 small t rial was ident if ied for this comparison, thus publicat ion bias was highly
suspected.
4 Downgraded once: inconsistency: unexplained heterogeneity was high between included studies.
5
H
y
d
ro
m
o
rp
h
o
n
e
fo
r
c
a
n
c
e
r
p
a
in
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
This review updates and replaces the previously published ’Hy-
dromorphone for acute and chronic pain’ review which was with-
drawn as the original author team were unavailable to update the
review (Quigley 2013). The scope of the current review is limited
to cancer pain.
Description of the condition
Pain is defined as “an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or described in
terms of such damage” (IASP 2011).
Cancer pain is an important and distressing symptom of the dis-
ease, which tends to increase in frequency and intensity as the
cancer advances. For people with cancer, pain can arise from the
progression of the cancer itself as well as from treatments designed
to alleviate the condition such as radiotherapy, chemotherapy and
surgery. Cancer-related pain can be classified as acute or chronic,
though it is sometimes thought to be an ongoing acute pain.
Acute pain is defined as having “a temporal pattern of onset...
generally associated with subjective and objective physical signs”
(Meier 2010), whereas chronic pain is more continuous, lasting
six months or longer (Meier 2010).
One previous systematic review indicated the prevalence of pain
to be more than 50% in all cancer types (Van den Beuken-van
Everdingen 2007). For people with advanced cancer, the preva-
lence of pain can be as high as 90% (Laird 2008). It has been
estimated that 30% to 50% of people with cancer categorise their
pain as moderate to severe and that between 75% and 90% of peo-
ple with cancer experience pain which has a major impact on their
daily life (Portenoy 1999). Epidemiological studies suggest that
approximately 15% of people with cancer who experience pain
fail to experience acceptable pain relief with conventional man-
agement (Running 2011; Yakovlev 2008). Uncontrolled pain can
lead to physical and psychological distress and can have a drastic
effect on people’s quality of life.
Description of the intervention
The options available for managing cancer-related pain include
pharmacological treatments (e.g. opioid analgesics), psychologi-
cal therapy (e.g. cognitive behavioural therapy) and alternative
treatments (e.g. acupuncture or massage). Opioid pharmacother-
apy (such as morphine, oxycodone, fentanyl, hydromorphone and
methadone) are the most effective of these therapies (Portenoy
2011).
The World Health Organization (WHO) has recommended oral
morphine as the first choice for the management of moderate to
severe cancer-related pain (WHO 1986). This recommendation is
largely due to its cost and availability rather thanproven superiority
(Caraceni 2012), with a previous review suggesting that a signifi-
cant proportion of people do not achieve sufficient pain relief by
taking morphine due to unmanageable adverse events, including
nausea, delirium or myoclonus (muscle spasm) (Murray 2005).
However, evidence from one Cochrane Review on oral morphine
for cancer pain suggested that only around 5% of participants
stopped taking morphine due to lack of pain relief or unacceptable
adverse events (Wiffen 2013). Morphine has also been associated
with toxicity in people with renal impairment (King 2011a).
Hydromorphone (also known as dihydromorphinone) is a semi-
synthetic derivative of morphine, and is marketed in various coun-
tries under a range of brand names. Since its clinical introduc-
tion in 1926, it has been used as an alternative opioid analgesic to
morphine, as it has a similar chemical structure but is more lipid
soluble (Urquhart 1988) and potent (Twycross 1994). Hydromor-
phone hydrochloride has high aqueous solubility and is beneficial
for people who require higher doses (Portenoy 2011), and OROS
(osmotic-controlled release oral delivery system) hydromorphone
extended-release (ER) is five times as potent as morphine, and has
8.5 times the equianalgesic effectwhen administered intravenously
(Binsfeld 2010; Sarhill 2001). This also allows a smaller dose of
hydromorphone to be used for an equianalgesic effect. Hydro-
morphone is administered through several routes (e.g. oral, intra-
venous, subcutaneous, epidural and intrathecal) (Murray 2005).
Hydromorphone is represented in several international guidelines
for the treatment of pain. For the management of chronic cancer
pain, including break-through pain, the WHO uses a model of a
three-step ladder, inwhich step-one therapy consists of non-opioid
analgesics with or without adjuvant therapy. For persistent or in-
creasing pain, an opioid for mild to moderate pain (e.g. tramadol,
codeine) might be added. If this combination fails to relieve the
pain or if the pain increases, an opioid for moderate to severe pain
(e.g. morphine, methadone, hydromorphone, oxycodone or fen-
tanyl) should be substituted (Ambrosio 2003). Recommendations
issued by the European Association for Palliative Care in 2012
agree with the three-step process and additionally suggest that hy-
dromorphone be included as a step-two opioid when used at low
doses (e.g. 4 mg/day) (Caraceni 2012). Consensus-based guide-
lines for the intrathecal treatment of cancer pain propose using in-
trathecal morphine as first-, second- or third-line therapy for peo-
ple with moderate to severe intractable cancer pain (Deer 2011).
For chronic non-cancer pain, the American Society of Interven-
tional Pain Physicians includes hydromorphone in their guidelines
for the use of opioids (Trescot 2006).
How the intervention might work
Like morphine, hydromorphone is primarily an agonist at µ-opi-
oid receptors, displaying weak affinity for κ-opioid receptors. µ-
Opioid receptors mediate pain-relieving properties but they can
also result in adverse events such as nausea, constipation and respi-
ratory depression (Murray 2005). One systematic review showed
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that hydromorphone has similar analgesic and adverse effects to
morphine (Miller 1999), while a more recent review concluded
that no study has yet clearly demonstrated whether hydromor-
phone is better than oral morphine (Pigni 2011).
Hydromorphone, in common with other opioid analgesics, has
the potential to produce adverse events that include respiratory
depression, nausea, vomiting, constipation and itching. Tolerance
may develop during chronic opioid therapy such that larger doses
may be required to sustain the analgesic effect. In addition, people
can be at risk of physiological dependence and experience opioid
withdrawal syndrome upon sudden cessation of the opioid or ad-
ministration of an antagonist. When used for the relief of pain
in malignant disease, the actions of relieving anxiety, producing
drowsiness and allowing sleep may be welcome (Grahame-Smith
2002).
Why it is important to do this review
This is one of a suite of reviews investigating analgesics for cancer
pain. Although WHO recommends oral morphine as a first-line
analgesia for cancer-related pain, the use of hydromorphone re-
mains a consideration in some circumstances (Wiffen 2013). Pre-
vious systematic reviews have compared the efficacy and adverse
effects of hydromorphone with other medications, but the incon-
sistency of their conclusions and the limited (low to moderate)
methodological quality of the studies that were included suggested
that further research is needed (Pigni 2011). This review updates
the evidence by evaluating the effectiveness of hydromorphone for
cancer-related pain and examines the incidence and severity of its
adverse effects.
O B J E C T I V E S
To determine the analgesic efficacy of hydromorphone in relieving
cancer pain, as well as the incidence and severity of any adverse
events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that focused on
hydromorphone for the treatment of cancer pain and assessed pain
as an outcome measure in this review. The RCTs included parallel
or cross-over studies of any duration. We excluded studies which
did not state that participants were allocated at random.
Types of participants
We intended to include studies of both adults and children with
moderate to severe cancer pain (as defined in each study) whowere
clinically assessed as requiring treatment with opioid analgesia.
Types of interventions
We included studies inwhich hydromorphone (any dose and route
of administration) was the active intervention. Comparison treat-
ments included placebo, an alternative opioid or another active
control.
Types of outcome measures
We assessed participant-reported pain intensity and pain relief
through the use of validated pain scales, including visual analogue
scales (VAS) and categorical scales. Where possible, we collected
data on the four main outcomes previously highlighted as impor-
tant to people with cancer (Moore 2013); pain no worse than
mild, and the impact of the treatment on consciousness, appetite
and thirst (Wiffen 2014).
Primary outcomes
• Participant-reported pain intensity levels as measured using
a validated VAS or categorical pain scale. We were particularly
interested in, but not limited to, numbers of participants who
achieve ’no worse than mild pain’ (Moore 2013). “No or mild
pain” has been previously considered as: 3/10 on a numerical
rating scale, or 30/100 mm on a VAS (Wiffen 2013). We did not
consider physician, nurse or carer-reported measures of pain.
• Participant-reported pain relief measured using a validated
scale.
Secondary outcomes
• Adverse events, for example, drowsiness/sedation, nausea
and constipation, impact of the treatment on consciousness,
appetite and thirst (incidence and severity, as defined and
measured in each study).
• Improvement in participants’ quality of life measured using
the EuroQol EQ-5D, the World Health Organization Quality of
Life Assessment or a similar validated quality of life instrument.
• Leaving the study early or discontinuation of treatment for
any reason.
• Death.
Search methods for identification of studies
Electronic searches
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To identify potentially relevant studies to be assessed for inclusion
in this review, we searched the databases listed below. See Appendix
1 for search strategies.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 3) in the Cochrane Library.
• MEDLINE (Ovid) 1946 to April 2016.
• Embase (Ovid) 1974 to April 2016.
Searching other resources
In an attempt to identify any relevant published or unpublished
reports not found in the electronic searches, we manually checked
the references of each included paper.We contacted the authors of
each included paper and of publications which were only available
in abstract format. Where possible, we contacted representatives
from the pharmaceutical companiesmarketinghydromorphone to
ask for any relevant published or unpublished studies, or missing
data.
There was no limitation on publication date or on language. Had
there been any non-English papers, we would have translated
as necessary. We also searched for ongoing trials in ClinicalTri-
als.gov (www.clinicaltrials.gov) and theWHO International Clin-
ical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).
We intended to search metaRegister of controlled trials (mRCT)
(www.controlled-trials.com/mrct), however, the website was un-
available.
Data collection and analysis
Selection of studies
Two review authors (YJB and BJH) assessed the titles and abstracts
of all studies identified by the searches and independently con-
sidered the full records of all potentially relevant studies for in-
clusion by applying the selection criteria outlined in the Criteria
for considering studies for this review section. We resolved dis-
agreements by discussion. We did not restrict the inclusion criteria
by date or language. To promote transparency of the search and
systematic review process, we produced a PRISMA flow diagram
(Figure 1), as per the PRISMA statement (Moher 2009).
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Figure 1. Study flow diagram.
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Data extraction and management
Weextracted data using theCochrane Pain, Palliative andSupport-
ive Care Group’s recommended data extraction form and recorded
baseline data on participants, details of interventions, outcomes
and results relevant to our review. Hadwe identified any study that
included a subset of participants who received hydromorphone,
we would have extracted data from this group. We resolved any
disputes by discussion.
Assessment of risk of bias in included studies
Two review authors (YJB and BJH) independently assessed the
methodological quality of each included study using the ’Risk of
bias’ assessment method outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). This included
the following risk of bias domains: allocation and randomisation
methods; blinding and methods of maintaining blinding; selec-
tive reporting of outcomemeasures; incomplete outcome data and
’other’ sources of bias (e.g. sources of funding). We rated the do-
mains as ’low risk’, ’high risk’ or ’unclear risk’ of bias. We com-
pleted a ’Risk of bias’ table for each included study. We resolved
any disagreements between the assessors by discussion. Small stud-
ies have been shown to overestimate treatment effects, probably
due to methodological weaknesses (Moore 2012; Nüesch 2010);
therefore, we considered studies to be at low risk of bias if they
had 200 or more participants per treatment arm, at unclear risk if
they had between 50 and 200 participants per treatment arm, and
at high risk if they had fewer than 50 participants per treatment
arm (Wiffen 2013).
Measures of treatment effect
For dichotomous outcomes, we calculated the risk ratio (RR) and
the corresponding 95% confidence interval (CI) and P value. For
continuous outcomes, we calculated the mean difference (MD)
and its corresponding 95% CI when means and standard devi-
ations (SD) were available. If such information was unavailable,
we would have use the methods described in Chapter 16 of the
Cochrane Handbook for Systematic Reviews of Interventions to cal-
culate standardised mean differences (SMD) from, for example, F
ratios, t values, Chi2 values and correlation coefficients (Higgins
2011). In cases where continuous measures were used to assess the
same outcomes using different scales, we would have pooled these
data usingHedges’ g to estimate the SMD.When effect sizes could
not be pooled, we would have reported study-level effects narra-
tively. We would also have calculated numbers needed to treat for
an additional outcome (NNTB) and additional harmful outcomes
(NNTH).
Unit of analysis issues
We only included studies that randomised the individual partici-
pant.
Dealing with missing data
We assessed missing data in the included studies. Where possible,
we investigated and reported the reasons and numbers of those
dropping out of each included study. Where studies were identi-
fied as having missing data, we initially attempted to contact the
study authors to obtain this information. For dichotomous out-
comes, we performed an intention-to-treat (ITT) analysis. If there
was missing participant information, we recorded this and com-
mented in the individual study’s ’Risk of bias’ table. We assigned
participants with missing data to a ’zero improvement’ category,
and we performed a sensitivity analysis comparing the resulting ef-
fect sizes with those obtained using completer-only data. For con-
tinuous outcomes, we intended to use baseline observation carried
forward (BOCF), where rating scales were employed. However,
this was not done as data of the few continuous outcomes were
skewed. Where data are missing for substantial numbers of par-
ticipants (greater than 10%), we rated the study as a high risk of
bias.
Assessment of heterogeneity
We intended to assess for heterogeneity among primary outcome
studies using the I2 statistic alongwith its corresponding P andChi
2 values (Higgins 2011), and discuss any observed heterogeneity
and its magnitude. Had we identified heterogeneity, we would
have investigated possible sources using subgroup analyses and
sensitivity analyses.
Assessment of reporting biases
We looked for the original trial protocols of the included studies
and compared the results to these when theywere found.Whenno
protocol was available, we compared the reported outcomes against
the methods section of the paper to look for selective reporting of
outcomes.
Data synthesis
We entered all extracted data into Review Manager 5 software
for analysis (RevMan 2014). In order to take into account differ-
ences between studies, we synthesised data using a random-effects
model. We used a fixed-effect model in a sensitivity analysis in
order to investigate any differences in the estimate of effect. We
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meta-analysed the data where possible. Where this was not feasi-
ble, we summarised data narratively in the results and discussion
sections and the relevant tables.
Grading of evidence
This section is taken from theCochraneDrugs andAlcoholGroup
recommended text. We assessed the overall quality of the evidence
for each outcome using the GRADE system (Guyatt 2011), and
presented it in the ’Summary of findings’ tables, to present the
main findings of a review in a transparent and simple tabular
format. In particular, we included key information concerning the
quality of evidence, the magnitude of effect of the interventions
examined and the sum of available data on the main outcomes.
The GRADE system uses the following criteria for assigning grade
of evidence:
• high = further research is very unlikely to change our
confidence in the estimate of effect;
• moderate = further research is likely to have an important
impact on our confidence in the estimate of effect and may
change the estimate;
• low = further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate;
• very low = any estimate of effect is very uncertain.
We decreased grade if there was:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1);
• high probability of reporting bias (-1).
’Summary of findings’ table
We included two ’Summary of findings’ tables to present the main
findings in a transparent and simple tabular format. In particular,
we include key information concerning the quality of evidence,
the magnitude of effect of the interventions examined and the
sum of available data on the outcomes participant-reported pain
intensity, adverse events, leaving the study early and death.
Subgroup analysis and investigation of heterogeneity
Had there been data available, we would have carried out the
following subgroup analyses:
• method of administration (long-acting versus short-acting);
• single dose versus multiple dose;
• type of cancer;
• age (adults versus children).
Sensitivity analysis
Had there been sufficient data available, we would have examined
the robustness of meta-analyses by conducting a sensitivity analy-
sis. In future updates of this review, we plan to exclude studies are
at ’high risk of bias’ across any one of the risk of bias domains in
order to assess any differences in the estimate of treatment effect.
We further plan to conduct a sensitivity analysis for high levels
of attrition (greater than 10%) in individual studies, comparing
completer-only data with our assumptions of ITT and to assess
any differences when synthesising data using a fixed-effect rather
than a random-effects model.
R E S U L T S
Description of studies
Results of the search
Details of the search results are illustrated in the PRISMA table
(Figure 1).
In the original search, we found 512 (375 through databases and
137 through international ongoing clinical trial registries) records
that were potentially relevant. After removing duplicate records,
we screened 449 abstracts, of which we were able to exclude 438
records that were clearly irrelevant. We eventually identified 11
full-text articles as potentially eligible for inclusion. Upon close
inspection of these papers, we were able to include four studies
(with six references) in this review. There was one ongoing study
and there are no studies awaiting assessment.
Included studies
We found four RCTs in adults (604 participants) that satisfied
the inclusion criteria of this review; see Characteristics of included
studies for a full description.The search foundno studies including
children.
Design and setting
Three of the included studies were conducted in high-income
countries. Hagen 1997 was conducted in Canada; Hanna 2008
was a multicentre trial involving 37 centres in Belgium, Canada,
France, Germany, the Netherlands, Spain, Sweden and the UK.
This study reported that it included inpatients, outpatients andday
patients. Moriarty 1999 was conducted in the UK. The remaining
study was conducted in China (Yu 2014).
Two studies had a cross-over study design (Hagen 1997; Moriarty
1999), and two had a two-stage, parallel design that included an
initial titration stage followed by a slow release (SR) or mainte-
nance phase (Hanna 2008; Yu 2014).
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Sample sizes
Hagen 1997 was the smaller trial of the four with 44 participants
randomised, but only 31 people completed the trial. Hanna 2008
had a sample size of 200. Moriarty 1999 randomised 100 partici-
pants, but only 89 completed the trial. Yu 2014 randomised 260
people, but only 137 completed the trial through to the end of
maintenance phase.
Participants
All four studies included adults with chronic cancer pain. The
mean age in Hagen 1997, Hanna 2008, and Yu 2014 was about
56 to 59 years with evenly distributed gender; the age of Moriarty
1999 was over 18 years but no age range was given. We found no
studies including children. The proportion of men in the study
ranged from 42% (Hagen 1997) to 66% (Yu 2014).
The severity of cancer pain was unclear in Hagen 1997, but par-
ticipants required stable analgesics. Participants in Hanna 2008
had moderate to severe pain and required 60 mg to 540 mg of
oral morphine every 24 hours at baseline. Moriarty 1999 and Yu
2014 also involved people with moderate to severe cancer pain.
The locations of the primary tumour were mainly breast, colorec-
tal, lung, prostate, gastrointestinal and central nervous system. A
smaller proportion of participants had cancer in the oral cavity,
lymphoma, leukaemia and bone cancer.
Interventions
Interventions included hydromorphone versus oxycodone (Hagen
1997; Yu 2014), and hydromorphone versus morphine (Hanna
2008; Moriarty 1999).
Hagen 1997 compared controlled release (CR) hydromorphone
versus CR oxycodone given every 12 hours for seven days. The
mean (± SD) daily doses were given as 24 ± 4 mg for hydromor-
phone and 120 ± 22 mg for oxycodone. Cross-over was completed
without a washout period.
In the two-stage Yu 2014 trial, the eight-day titration phase was
followed by a 28-day maintenance phase. Both phases used CR
formulations; OROS hydromorphone or oxycodone CR and the
maximum daily doses were 32 mg forOROS hydromorphone and
80 mg for oxycodone CR.
The titration stage for Hanna 2008 used instant release (IR) for-
mulations of either hydromorphone or morphine given every four
hours (six times daily) for two to nine days. The titrated dosage
of hydromorphone during this phase was 12 mg/day to 108 mg/
day and for morphine was 62 mg/day to 540 mg/day. This was
followed by a 10- to 15-day SR stage, when the same drugs were
given but in a CR formulation; OROS hydromorphone once daily
or morphine CR twice daily. The starting dose was the same level
as dose-stable pain achieved in IR phase, adjusted as required every
two days at most.
Moriarty 1999 used tablet formulation of hydromorphone CR 4
mg and morphine CR 30 mg.
Outcomes
We were able to collect data on pain intensity, but the data were
skewed. Other outcomes reported by the studies included adverse
events, death and leaving the study early.
Excluded studies
Weexcluded four studies. Although all of themhad relevant partic-
ipants and interventions, they were not RCTs. See Characteristics
of excluded studies for further details (Han 2014; Lee 2012; Wirz
2008; Wirz 2009).
Studies awaiting assessment
There are no studies awaiting assessment.
Ongoing studies
The search found one ongoing RCT eligible for inclusion, which
compared hydromorphone with oxycodone and fentanyl patch in
adults with moderate to severe cancer pain (NCT02084355). The
total sample size of this study was unclear. Expected completion
date was January 2016.
Risk of bias in included studies
The general risk of bias in respect of study design and conduct
was low. However, two trials were industry funded (Hagen 1997;
Hanna 2008), which raised some concern over potential conflicts
of interest. Furthermore, Hagen 1997 had a high dropout rate and
those dropping out were excluded from their final analysis. See
Figure 2 and Figure 3 for graphic representation of the risk of bias
assessment.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We assigned all four included studies low risk of bias for random
sequence generation. Hanna 2008 randomised participants on a 1:
1 ratio via a central computer-generated randomisation list. Simi-
larly, Yu2014 also used central randomisation (1:1) using anonline
dynamic minimisation allocation program. Hagen 1997 did not
describe randomisation procedure in detail, but it was a double-
blind trial, thus it was likely to have had adequate randomisation.
Moriarty 1999 employed a third-party randomisation method.
Allocation concealment
None of the studies provided explicit detail on allocation conceal-
ment. We considered Hanna 2008 was more likely to have used
concealment since the randomisation was done via a central list,
and so we judged this study at low risk of bias. We also judged
Moriarty 1999 and Yu 2014 at low risk of bias because they used
third-party randomisation,which typically conceals allocation.We
judged Hagen 1997 at unclear risk of bias because there was no
detail reported in the paper, thus review authors were unable to
make any conclusive judgement.
Blinding
Blinding of participants and personnel
Three of the four studies were described as double-blind (Hagen
1997; Hanna 2008; Moriarty 1999). Hanna 2008 was reported
as double blind, but without further description of the blinding
method; in this case, we accepted the author’s reporting as true
and accurate, thus rated it at low risk of bias. Hagen 1997 and
Moriarty 1999 used double-blind and double-dummy to protect
the blinding. Yu 2014 did not offer an explicit description on
blinding; however, review authors felt that double-blinding was
likely to have been used, as the study employed over-encapsulated
tablet and placebo to mask blinding, hence we rated it at low risk
of bias.
Blinding of outcome assessment
It was unclear in any of the studies if the outcome assessment
was blinded, because none of the included studies provided an
explicit description of this risk domain. Therefore, we rated this
risk domain at unclear risk for all of the four studies.
Incomplete outcome data
Dropout was common and the proportion of dropout exceeded
10% in all four studies, thus the general risk of bias in this do-
main was high. Hanna 2008 had applied ITT analysis and the
reasons and proportion for dropout was similar between groups,
however, the dropout rate was greater than 10%, thus it was rated
as high risk. Hagen 1997 was rated as high risk as it had over 10%
dropout and these were excluded from final analysis, which fur-
ther compromised the already weakened evidence. Moriarty 1999
had 11 (11%) participants drop out with reasons given and were
included in the final analysis. The dropout rate was over 10%,
but only marginally so. We felt the drop-out was unlikely to have
caused significant bias, as reasons and proportion of dropout were
comparable between groups. We therefore judged this study to be
at a low risk of bias for this domain. Sixty (46%) people dropped
out of the hydromorphone group and 63 (48%) people dropped
out of the oxycodone group in Yu 2014, but the proportion and
reasons were balanced between groups. Nevertheless, we judged it
as high risk because the dropout rate was greater than 10%.
Selective reporting
Two of the four trials had protocols (Hanna 2008; Yu 2014), and
we did not identify any differences between the planned outcome
measures in the protocol and the reported outcome measures in
the full report. Two trials had no available protocols (Hagen 1997;
Moriarty 1999). We compared the reported outcomes with the
paper’s methodology section and did not find any evidence of
selective reporting. Therefore, we judged all four included studies
as being at low risk of reporting bias.
Other potential sources of bias
We judged three included studies to be at a high risk of bias for
this domain (Hagen 1997; Hanna 2008; Moriarty 1999). There
were two major concerns of other bias regarding sample size and
sponsorship. Two studies were funded by pharmaceutical compa-
nies (Hagen 1997; Hanna 2008). One of the authors of Moriarty
1999 was an employee of a pharmaceutical company, which raised
concern over conflict of interest. Three of the four studies had a
small sample size (fewer than 200 participants per treatment arm),
which raised potential risk of bias (Hagen 1997; Hanna 2008;
Moriarty 1999). Yu 2014 had between 50 and 199 participants
per treatment arm, and so we judged this study at unclear risk of
bias for this domain.
Effects of interventions
See: Summary of findings for the main comparison
Hydromorphone compared to oxycodone for cancer pain;
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Summary of findings 2Hydromorphone compared to morphine
for cancer pain
We were able to extract numerical data from three of the four
included studies.
Comparison 1: hydromorphone versus oxycodone
This particular comparison had very low quality evidence from
Hagen 1997 (n = 44) and Yu 2014 (n = 260) (Summary of findings
for the main comparison), downgraded three times due to risk of
bias, imprecision, publication bias or inconsistency.
1.1 Participant-reported pain intensity
Data were presented in separate data tables because they were
skewed. Hagen 1997 reported VAS score (0 to 100 with higher
score indicating worse outcome). The mean VAS endpoint pain
intensity scores at seven days were similar between groups (mean (±
SD): hydromorphone 28.86 ± 17.08, n = 19; oxycodone 30.30 ±
25.33, n = 12), although the SD of the oxycodone group was larger
than for the hydromorphone group indicating a wider spread of
the data. Both groups achieved no worse than mild pain on the
categorical pain intensity asmeasured on a four-point VAS (higher
= worse outcome) (hydromorphone 1.5 ± 0.1 points; oxycodone
1.4 ± 0.1 points).
Yu 2014 reported Brief Pain Inventory (BPI) score (0 to 10 with
higher score indicating worse outcome). The BPI change score of
’pain at its worst in the past 24 hours’ from baseline was similar
between groups at 28 days (hydromorphone -1.8 ± 3.29, n = 40;
oxycodone -1.7 ± 3.91, n = 41). BPI score for ’mean pain in the
past 24 hours’ of the same study showed that both groups achieved
no worse than mild pain (hydromorphone 2.9; oxycodone 3.3,
SDs not reported, n = 81) (Analysis 1.1).
Neither study reported ’no worse than mild pain’.
1.2 Participant-reported pain relief
Neither study reported participant-reported pain relief.
1.3 Adverse events
Hagen 1997 presented data measured using VAS at seven days in
separate data tables because the continuous data for this outcome
were skewed. The mean endpoint nausea scores were compara-
ble between groups (hydromorphone 16.05 ± 17.51, n = 19; oxy-
codone 16.68 ± 21.53, n = 12). However, the oxycodone group
had a higher mean endpoint sedation score than the hydromor-
phone group (hydromorphone 19.92 ± 20.62, n = 19; oxycodone
24.81 ± 25.73, n = 12), although we were not certain if the dif-
ference was statistically significant.
The above findings were consistent with Yu 2014, which indicated
no significant differences between groups at 28 days on the fol-
lowing adverse events: nausea (RR 0.94, 95% CI 0.67 to 1.32);
constipation (RR 0.94, 95% CI 0.67 to 1.32) and vomiting (RR
0.90, 95% CI 0.65 to 1.26). Other adverse events identified in
this study showed no significant differences between groups. See
Table 1 for further details.
Neither study reported impact on consciousness, appetite or thirst.
1.4 Quality of life
Neither study reported quality of life.
1.5 Leaving the study early
Two studies involving 304 participants reported on participants
leaving the study early (Hagen 1997; Yu 2014). We found no
evidence of difference between hydromorphone and oxycodone
(RR 0.61, 95% CI 0.20 to 1.87) (Analysis 1.4).
1.6 Death
One study reported death (n = 260) (Yu 2014). This was claimed
to be a consequence of disease progression, and there was no sta-
tistically significant difference between groups (RR 0.50, 95% CI
0.22 to 1.13) (Analysis 1.5).
Comparison 2: hydromorphone versus morphine
In this comparison, there was very low quality evidence from a
single study (Hanna 2008, n = 200). The other study which in-
vestigated these interventions did not report any usable numerical
data for analysis (Moriarty 1999) (Summary of findings 2, down-
graded three times due to risk of bias, imprecision and publication
bias).
2.1 Participant-reported pain intensity: BPI endpoint (SR
phase) subscale score (high = more pain; data skewed)
The continuous data from one RCT were too skewed to report
in a graph. Therefore, we have presented them in a data table
(Analysis 2.1). Subscale data derived from the BPI scale showed
that themorphine group appeared to have a higher endpoint mean
score on ’worst pain’ (mean ± SD: hydromorphone 3.5 ± 2.9, n
= 99; morphine 4.3 ± 3.0, n = 101), nevertheless, mean scores on
’least pain’ and ’mean pain’ were almost identical. The ’mean pain’
subscale data showed that both groups achieved no worse than
mild pain (see Analysis 2.1).
Although it was not possible to extract and analyse data by groups
fromMoriarty 1999, the study gave a clear indication that partic-
ipants in both groups achieved no worse than mild pain as mea-
sured by VAS. The mean score of both groups was below 20 on
the 0- to 100-mm VAS.
We found no studies reporting the number of participants who
achieved ’no worse than mild pain’
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2.2 Participant-reported pain relief
Neither study reported participant-reported pain relief.
2.3 Adverse events
One study reported adverse events (Hanna 2008). There was no
difference between groups for the following adverse events:
• anaemia (hydromorphone 25/77; morphine 21/86; RR
1.21, 95% CI 0.73 to 2.02);
• anorexia (hydromorphone 24/77; morphine 20/86; RR
1.22, 95% CI 0.72 to 2.07);
• anxiety (hydromorphone 27/77; morphine 16/86; RR
1.72, 95% CI 0.99 to 2.99);
• asthenia (hydromorphone 28/77; morphine 19/86; RR
1.50, 95% CI 0.9 to 2.51);
• dizziness (hydromorphone 26/77; morphine 23/86; RR
1.15, 95% CI 0.71 to 1.88);
• fatigue (hydromorphone 26/77; morphine 21/86; RR 1.26,
95% CI 0.76 to 2.09);
• headache (hydromorphone 25/77; morphine 17/86; RR
1.50, 95% CI 0.87 to 2.60);
• insomnia (hydromorphone 27/77; morphine 19/86; RR
1.45, 95% CI 0.86 to 2.43);
• nausea (hydromorphone 37/77; morphine 40/86; RR 0.94,
95% CI 0.66 to 1.34);
• peripheral oedema (hydromorphone 23/77; morphine 23/
86; RR 1.02, 95% CI 0.61 to 1.69);
• pruritus (hydromorphone 25/77; morphine 20/86; RR
1.28, 95% CI 0.76 to 2.14);
• pyrexia (hydromorphone 26/77; morphine 17/86; RR
1.56, 95% CI 0.9 to 2.69);
• somnolence (hydromorphone 30/77; morphine 27/86; RR
1.13, 95% CI 0.73 to 1.76);
• vomiting (hydromorphone 29/77; morphine 34/86; RR
0.87, 95% CI 0.58 to 1.31).
There was a statistically significant difference favouring the mor-
phine group on the following outcomes. However, the stability of
these analysis results is compromised by missing data, and two of
the outcomes (confusion and diarrhoea) were no longer statisti-
cally significant once we had taken into account the missing data
in a sensitivity analysis. See ’Comparison 2: sensitivity analysis for
hydromorphone versus morphine’ for further details.
• Confusion (hydromorphone 29/77; morphine 17/86; RR
1.74, 95% CI 1.02 to 2.96).
• Constipation (hydromorphone 52/77; morphine 34/86;
RR 1.56, 95% CI 1.12 to 2.17).
• Diarrhoea (hydromorphone 29/77; morphine 17/86; RR
1.74, 95% CI 1.02 to 2.96).
The Hanna 2008 study did not report impact on consciousness,
appetite or thirst.
Moriarty 1999 observed similar adverse events, but did not report
the number of participants, thus preventing pooling of the results.
The type and number of adverse events appeared to be balanced
between groups without any obvious differences. See Table 2 for
a detailed account.
2.4 Quality of life
We found no studies reporting quality of life.
2.5 Leaving the study early
2.5.1 Overall
One study (with 200 participants) reported leaving study early
(Hanna 2008) (Analysis 2.3). For this subgroup, we found no
evidence of a clear difference betweenOROShydromorphone and
morphine sulphate (RR 1.42, 95% CI 0.95 to 2.12).
2.5.2 Due to adverse events
One study (with 200 people) reported leaving the study early due
to adverse events (Hanna 2008) (Analysis 2.3). For this subgroup,
we found no evidence of a clear difference between the two treat-
ments (RR 1.39, 95% CI 0.67 to 2.88).
2.5.3 Due to lack of efficacy
One study (with 200 people) reported leaving the study early due
to lack of efficacy (Hanna 2008) (Analysis 2.3).However, we found
no evidence of a clear difference between the two treatments (RR
2.81, 95% CI 0.92 to 8.52).
2.6 Death
One trial (with 200 participants) reported death (Hanna 2008)
(Analysis 2.4). There was no clear difference between hydromor-
phone and morphine (RR 0.15, 95% CI 0.01 to 2.78).
Comparison 2: sensitivity analysis for hydromorphone
versus morphine
In accordance with our protocol, we performed a sensitivity anal-
ysis for the adverse events data reported by Hanna 2008 com-
paring the effect size with and without drop-outs. When we in-
cluded dropouts in the analysis, we found a statistically significant
difference favouring the morphine group for the following out-
comes: confusion (RR 1.74, 95% CI 1.02 to 2.96), constipation
(RR 1.56, 95% CI 1.12 to 2.17) and diarrhoea (RR 1.74, 95%
CI 1.02 to 2.96). However, when we analysed completers data,
only constipation remained statistically different (RR 1.76, 95%
CI 1.09, 2.87).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Hydromorphone compared to morphine for cancer pain
Patient or population: people with cancer pain
Setting: inpat ients, outpat ients and day pat ients
Intervention: hydromorphone
Comparison: morphine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Morphine Hydromorphone
Participant- reported
pain intensity
Pain intensity scores:
1 study (n = 200) using subscale data derived f rom BPI scale (0 to 10; higher = worse outcome):
mean (± SD) endpoint score for ’worst pain’ hydromorphone 3.5 ± 2.9 (n = 99); morphine 4.3 ± 3.0
(n = 101)
Mean scores on ’least pain’ and ’average pain’ were almost ident ical
No worse than mild pain:
1 study (n = 200) using subscale data derived f rom BPI scale (0 to 10; higher = worse outcome):
the ’average pain’ subscale data showed that both groups achieved no worse than mild pain
⊕©©©
Very low1,2,3
Higher mean endpoint
scores for ’worst pain’ in
morphine group
Similar scores for ’av-
erage’ and ’least ’ pain
in hydromorphone and
morphine groups
Both morphine and
hydromorphone groups
had mean pain levels of
’no worse than mild pain’
Adverse events - con-
fusion
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
Adverse events -
headache
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
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Adverse events - in-
somnia
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
Adverse events - nau-
sea
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
Adverse events -
pyrexia
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
Death
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
Leaving the study early
- overall
Follow-up: 24 days
See comment See comment Not est imable 200
(1 study)
⊕©©©
Very low1,2,3
We are uncertain if there
is any dif ference be-
tween intervent ions
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
BPI: Brief Pain Inventory; CI: conf idence interval; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded once: risk of bias: sample size < 200 per treatment arm.
2 Downgraded once: imprecision: sample size was smaller than opt imal information size; CI around est imate of ef fect was
wide and included no ef fect and appreciable benef it / harm.
3 Downgraded once: publicat ion bias: only 1 small t rial was ident if ied for this comparison, thus publicat ion bias was highly
suspected.
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D I S C U S S I O N
Summary of main results
We were only able to include four studies in this review, with a to-
tal sample size of 604 participants (data for 504 participants avail-
able for analysis). Two studies compared hydromorphone to oxy-
codone and two studies compared hydromorphone to morphine.
Overall, there was no evident difference in treatment efficacy be-
tween groups, and participants achieved no worse than mild pain
in all included studies (Hagen 1997;Hanna 2008;Moriarty 1999;
Yu 2014). Data on pain intensity demonstrated a similar effect be-
tween groups. There were several adverse events, but most showed
no difference between groups except for confusion, constipation
and diarrhoea, which favoured the morphine group. However, the
clinical significance of the observed differences are questionable
due to the instability of analysis caused by missing data from the
trial. Hanna 2008 reported three deaths in the morphine group
during the trial period, but trialists claimed that they were not
related to the drug but were the consequences of cancer. Yu 2014
also reported death (8 in the hydromorphone group and 16 in the
oxycodone group), but the most common reason was disease pro-
gression. The two studies that contributed themost data in this re-
view had over 10% dropout rates, but the reasons and proportion
of dropouts were balanced between groups (Hagen 1997; Hanna
2008). We hoped to observe effects on consciousness, thirst and
appetite, but the included studies did not report these data.
Prevalence of sleep disturbance in people with cancer ranges from
24% to 95% (Graci 2005; Mercadante 2004), and is more com-
mon among females with cancer, older people, and people with
depression or anxiety (Akechi 2007; Graci 2005). Therefore, we
suggest that more attention is given to pain control for increas-
ing quality of sleep (Graci 2005; Kvale 2006). Opioids are useful
for the initial restoration of night-time sleep (Graci 2005; Kvale
2006); however, long-term opioid use can cause sedation and day-
time sleeping, as well as disturbed sleep patterns and circadian
rhythms (Graci 2005; Hearson 2008). Unlike opioids and short-
acting hydromorphone, OROS hydromorphone is gradually ab-
sorbed over 24 hours without causing fluctuations in blood con-
centration (Nalamachu 2012). Hanna 2008 demonstrated that
pain levels in the evening were significantly lower after OROS hy-
dromorphone compared with CR morphine. Therefore, OROS
hydromorphone could be considered for people with cancer pain
with sleep disturbance.
Opioids are the mainstay of pain treatment. Knowledge regard-
ing the use of opioids can improve the care provided to people
with cancer. Opioid rotation is a common practice for the im-
provement of pain control or drug tolerability, or both (Quigley
2004).When these appropriate interventions have been exhausted
or when adverse effects are rapid and severe (or both), rotation to
an alternative opioid may help, but there is a lack of evidence to
support rotation.
Overall completeness and applicability of
evidence
There is a lack of data on children and younger adults. The mean
age of participants included in this review was approximately 56
years. We were able to collect data on the primary outcome of no
worse than mild pain and most of the secondary outcomes that we
intended to measure, with the exception of quality of life. There
was a lack of data on other participant-important outcomes, such
as the impact of the treatments on consciousness, appetite and
thirst. Applicability of the evidence is further limited by the fact
that only oxycodone and morphine were compared to hydromor-
phone in the included studies. Included studies were conducted
in high-income countries, which may have limited generalisability
in some lower-income countries.
There was a heterogeneity within the included trials with respects
to their study design, formulations used and duration of follow-up.
Two studies were cross-over design and two used a parallel design
using two phases. All of the studies used CR or ER opioids, yet one
study included an initial phase which used an IR formulation (
Hanna 2008). The duration of follow-up between the trials ranged
from 7 to 28 days. These factors increased the difficulty of drawing
specific conclusions from the studies.
It is worth noting that two of the trials in this review used the
OROS formulation of hydromorphone which has some unique
properties that differ from other formulations of hydromorphone
(Hanna 2008, n = 200; Yu 2014, n = 260). It is a unique long-act-
ing opioid formulation that utilises Push-Pull active osmotic tech-
nology and maintains consistent hydromorphone plasma concen-
trations throughout the 24-hour dosing interval, providing long-
lasting analgesia (Angst 2001; Drover 2002; Palangio 2002). The
dosage form controls the drug release into the body, almost in-
dependently from factors such as the surrounding pH or gastric
motility (Bass 2002; Verma 2002). There is a minimal effect of
food on the rate and extent of absorption of hydromorphone from
OROS hydromorphone (Sathyan 2007). It has been reported that
the pharmacokinetics of OROS hydromorphone are also mini-
mally affected by alcohol. These unique features ofOROSmay fur-
ther limit the generalisability of evidence. Similarly, we are aware of
other formulations of hydromorphone (and other opioids) which
may have potential benefits for specific groups of people with can-
cer but we found no evidence for these as part of this review.
Quality of the evidence
The four included studies (n = 604) were of low or unclear risk
of bias overall as they adopted appropriate study design, adequate
randomisation, and blinded participants and investigators. The
two most prominent risks of bias concerned sample size and spon-
sorship.One of the studies only had 44 participants (Hagen 1997),
and three studies were either funded or conducted by industry
(Hagen 1997; Hanna 2008; Moriarty 1999). The quality of the
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body of evidence was very low, mainly due to risk of bias caused by
small sample size and sponsorship with potential conflict of inter-
est, as well as imprecision around effect estimates and publication
bias. See Summary of findings for themain comparison; Summary
of findings 2 for detailed assessment results of each individual out-
come. The current body of evidence identified does not allow a
robust conclusion, as the majority of the data for the outcomes
were either skewed or had wide CIs around the estimated effect
size.
Potential biases in the review process
Although we searched mainstream biomedical databases and clin-
ical trials registries, searches beyond these resources to include
other non-English literature may improve the comprehensiveness
of the search results. Two review authors independently performed
screening and data extraction, but we were unable to extract any
data fromMoriarty 1999, which may have had some influence on
the results.
Agreements and disagreements with other
studies or reviews
The current review indicated little difference between hydromor-
phone and two other opioids, oxycodone and morphine, in terms
of analgesic efficacy. This finding is consistent with the 2012 Euro-
pean Association for Palliative Care (EAPC) guidelines (Caraceni
2012), which included a series of systematic reviews reviewing the
evidence for opioids in people with moderate to severe cancer pain
(Caraceni 2011; King 2011a; King 2011b; Pigni 2011). The re-
views concluded that there is a lack of evidence to demonstrate
superiority or inferiority of hydromorphone in comparison with
other analgesics and EAPC makes a weak recommendation that
hydromorphone,morphine or oxycodone could be used as the first
choice for step three of the WHO analgesic ladder. The results of
this review do not differ from the results of the previous Cochrane
Review (Quigley 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with cancer pain
Based on data gathered from the four included trials, it appears
that hydromorphone has a similar effect on participant-reported
pain intensity as oxycodone and morphine for adults with mod-
erate to severe cancer pain. There was no evident comparative
difference in analgesic effect between hydromorphone and other
opioids investigated in this review and, on average, participants
achieved no worse than mild pain on all investigated treatments.
There were several adverse events, but generally there was no dif-
ference between groups. In summary, the evidence suggests that
hydromorphone has a similar therapeutic effect and adverse effects
to oxycodone and morphine in adults with moderate to severe
chronic cancer pain. However, this finding should be applied with
caution for it only included four studies with different designs and
limited sample size. There were no data available for children or
for some important outcomes such as impact of the treatment on
consciousness, appetite and thirst.
For clinicians
Based on four included trials with different designs and limited
number of participants, we found a lack of evidence to support a
preference for hydromorphone over other opioid analgesics such
as morphine and oxycodone. The treatment effect of hydromor-
phone appeared to be similar to that of the comparator drugs for
adults with moderate to severe cancer pain. There were minor ad-
verse events in all treatment groups and generally no significant
difference between groups. However, most of the outcome data
were based on single randomised controlled trials with small sam-
ple size, thus the findings of the current review should be inter-
preted and applied with caution. We found no data for children.
The insufficient evidence requires clinicians to balance potential
benefits against potential adverse events on the merit of each in-
dividual case when recommending treatment in clinical practice.
For policy makers
This review identified little evidence to support hydromorphone as
the first-, second- or third-line treatment for cancer pain.However,
evidence collated in the current review suggests hydromorphone
has a similar analgesic effect as morphine and oxycodone, it can be
considered as an alternative when other opioids result in excessive
adverse events such as sedation and respiratory depression, and
when people with cancer pain experience renal failure. We found
no data for children. Included studies were conducted in high-
income countries, which may compromise the external validity
of the review as some of the drugs investigated may have limited
accessibility in some lower-income countries. Finally, it is worth
noting that findings from the current review are mainly based on
small trials with different designs and limited sample size and some
risk of bias, therefore, should be applied with caution.
Implications for research
This review reveals a general lack of research in this subject area.
Future trials with significant numbers of participants (e.g. over
200 per treatment arm) are needed to evaluate the safety and effec-
tiveness of hydromorphone for the management of moderate to
severe cancer pain in adults. Future research is encouraged to in-
volve children and young adults to provide direct evidence in this
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population. Further adequately powered randomised controlled
trials should use standardised tools or scales to measure pain as
a primary outcome. More data on other secondary outcomes, as
well as the comparative effect of a more comprehensive range of
medications, would also be useful to enable the review to draw
a more reliable and conclusive effect. Longer-term toxicity data
should be collected if possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hagen 1997
Methods Allocation: randomised
Blindness: double-blind, double-dummy
Duration: pre-cross-over phase: 7 days in each phase. Total study duration 14 days
Funding: ’Purdue Frederick’, since renamed ’Purdue Pharma’
Setting: Canada. Unclear if these were inpatients or community patients
Design: cross-over
Participants Diagnosis: people with chronic cancer pain and stable analgesic requirements
n = 44 (31 analysed)
Age (mean ± SD): 56 ± 3 years
Sex: men 13; women 18
History: of the 31 participants who completed the study, location of primary tumour
was breast (7), colorectal (5), lung (1), urological/prostate (5), central nervous system
(4), unknown primary site (2) and other (7)
Included: people with chronic cancer pain and stable analgesic requirements
Exclusion: known hypersensitivity to opioid analgesics; intolerance of oxycodone or
hydromorphone; presence of a medical or surgical condition likely to interfere with drug
absorption in the gastrointestinal tract; concurrent use of other opioid analgesics during
the study period; presence of intractable nausea or vomiting; people who had undergone
or were expected to undergo therapeutic procedures likely to influence their pain during
study period
Consent: “The study protocol and informed consent form received scientific and ethical
approval, and patients gave written informed consent before participating in the study”
(p. 1429)
Interventions • Hydromorphone CR, dose unknown (mean (± SD) daily dose reported as 24 ± 4
mg); n = 22 (19 completed study)
• Oxycodone CR, dose unknown (mean (± SD) daily dose reported as 120 ± 22
mg); n = 22 (12 completed study)
Each intervention was administered every 12 hours for 7 days pre-cross-over. No other
opioids permitted. Non-opioid analgesics that had been part of the person’s treatment
before the study were permitted. Incident and non-incident breakthrough pain was
treated with IR oxycodone and hydromorphone matching the active opioid analgesic at
a dosage of approximately 10% of the daily scheduled opioid dose
Outcomes Pain intensity VAS*
Pain intensity ordinal*
Sedation VAS*
Nausea VAS*
Dropouts*
Unable to use
Frequency of rescue analgesic use was not reported as there was no pre-cross-over data
Notes * Unpublished data obtained from Purdue Pharma
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Hagen 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Data only analysed for 31/44 participants.
Dropout rate > 10%
Selective reporting (reporting bias) Low risk None obvious
Other bias High risk Drug company-funded. Sample size small,
< 50 people per treatment arm
Hanna 2008
Methods Allocation: randomised
Blindness: double-blind
Duration: up to 24 days
Funding: Johnson & Johnson (previously ALZA Corporation)
Setting: multicentre (37 centres in Belgium, Canada, France, Germany, theNetherlands,
Spain, Sweden and the UK); inpatients, outpatients and day patients
Design: parallel
Participants Diagnosis: people with moderate to severe chronic cancer pain requiring 60 mg to 540
mg of oral morphine (or equivalent) every 24 hours
n = 200
Age (mean): 59.8 years
Sex: 98 men (49%); 102 women (51%)
History: cancer type: breast (56), lung (39), genitourinary (30), gastrointestinal (32),
oral cavity (6), lymphoma (3), leukaemia (3), bone (2) and other (29)
Included: inpatients, outpatients and day patients ≥ 18 years of age; moderate to severe
chronic cancer pain; currently receiving strong oral or transdermal opioid analgesics (60
mg to 540 mg of oral morphine or equivalent every 24 hours); appropriate candidate
for strong oral or transdermal analgesics (anticipated requirement, 60 mg to 540 mg of
oral morphine or equivalent every 24 hours); pain suitable for treatment with a once-
daily formulation
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Hanna 2008 (Continued)
Exclusion: pain not considered potentially responsive to opioids; pain present only upon
movement; need for other opioid analgesics (except study medication and breakthrough
pain medication) after randomisation; current or recent (within 6 months) history of
drug or alcohol abuse (or both); pregnant or lactating, seeking pregnancy or failing to
take adequate contraceptive precautions; intolerance of, or hypersensitivity to, hydro-
morphone or other opioids; presence of gastrointestinal disease of sufficient severity to
likely interfere with oral analgesia (e.g. dysphagia, vomiting, no bowel movement or
bowel obstruction due to impaction within 5 days of study entry, severe gut narrowing
that may affect analgesic absorption or transit); use of monoamine oxidase inhibitors
within 2 weeks prior to study entry; investigational drug use within 4 weeks of study
entry; presence of conditions for which risks of opioid use outweigh potential benefits
(e.g. raised intracranial pressure, hypotension, hypothyroidism, asthma, reduced respi-
ratory reserve, prostatic hypertrophy, hepatic impairment, renal impairment, older and
debilitated people, convulsive disorders, Addison’s disease)
Consent: “All patients who entered the trial were informed of the nature of the study,
and provided written informed consent for participation. The study was conducted in
accordance with the principles of the Declaration of Helsinki.”
Interventions • Hydromorphone IR 12 mg/day to 108 mg/day; dose titrated to next higher dose
level if participant had > 3 breakthrough pain episodes requiring pain medication
within the previous 24 hours, maximum once a day, dose titration continued until
dose-stable pain* control achieved; n = 99
• Morphine IR 62 mg/day to 540 mg/day, dose titrated to next higher dose level if
participant had > 3 breakthrough pain episodes requiring pain medication within the
previous 24 hours, maximum once a day, dose titration continued until dose-stable
pain* control achieved; n = 101
Initial IR phase and subsequent SR phase
• IR phase: formulations of either hydromorphone (Dilaudid, Abbott Laboratories)
or morphine (morphine sulphate IR (Sevredol, Napp Laboratories)) every 4 hours (6
times daily) for 2 to 9 days. Individual dose levels based on participant characteristics
and selected according to available tablet strength and a working conversion ratio of 1:
5 (1 hydromorphone: 5 morphine equivalence). Concomitant chemotherapy or
radiotherapy was permitted.
• SR phase: duration 10 to 15 days: same drugs received but in SR formulation
(OROS hydromorphone, once daily, or CR morphine (morphine sulphate SR (MST
Continus, Napp Laboratories)), twice daily. Same starting dose level as dose-stable pain
achieved in IR phase, adjusted as required every 2 days at most.
* dose-stable pain control: defined as participants who experience 2 consecutive days
with ≤ 3 breakthrough pain episodes requiring rescue medication - they could then
begin SR phase of the study. Participants not achieving dose-stable pain control by day
9 were withdrawn from the study
Outcomes Pain (’worst pain in the past 24 hours’ item of the BPI)
Adverse events
Notes
Risk of bias
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Hanna 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised 1:1, with a
central computer-generated randomisation
list
Allocation concealment (selection bias) Low risk There was no explicit description on alloca-
tion concealment, but we considered con-
cealment is likely to have been used since
the randomisation was done via a central
list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind - no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals from study were addressed
Quote: “All efficacy variables were analyzed
using the intent-to-treat (ITT) population,
which included all patients who took at
least one dose of study medication and had
at least one assessment from each study
phase”
The proportion of dropout appeared to be
higher in hydromorphone group; however,
the reasons for dropout were comparable
between groups, thus review authors con-
sider the proportional difference between
groups is unlikely to have had an effect
on effect estimate. However, because the
dropout rate was > 10%, we rated this do-
main as high risk
Selective reporting (reporting bias) Low risk Detailed data of the following 2 scales were
not given: Mini-Mental State Examination
and Eastern Cooperative Oncology Group
performance status was administered, but
authors did comment that the assessment
scores were similar between groups
Other bias High risk Drug company-funded
One of writers was employed by Johnson
& Johnson (study sponsor)
Study size small, < 200 participants per
treatment arm
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Moriarty 1999
Methods Allocation: randomised
Blindness: double-blind, double-dummy
Duration: 6 days (with run-in period of 1 to 3 days)
Funding: not stated
Setting: not stated. Unclear if these were inpatients or community patients
Design: cross-over
Participants Diagnosis: people with cancer pain
n = 100
Age: not stated
Sex: men 53; women 47
History: most common of primary malignancies presented by participants were lung,
breast, gastrointestinal and genitourinary
Included: people aged ≥ 18 years, with cancer and achieving pain control with CR
morphine sulphate
Exclusion: people with significant respiratory depression; severe renal or hepatic im-
pairment; people taking strong opioid analgesics other than 12-hourly morphine sul-
phate, and people taking monoamine oxidase inhibitors currently or within the previous
2 weeks; pregnant (or not adequately protected from becoming pregnant) or lactating
women
Consent: no details
Interventions • Hydromorphone CR 4 mg
• Morphine CR 30 mg
Outcomes Pain VAS
Adverse events
Treatment preference
Use of rescue medication
Notes No pre-cross-over data available. No contact details available to request necessary infor-
mation
We are also unclear about the intensity of people’s cancer pain. This review only intended
to include people with moderate to severe cancer pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...according to a randomisation
schedule previously prepared by the clinical
supplies department at Napp Laboratories
Limited...”
Comment: third-party randomisation was
used and is likely to be low risk of bias
Allocation concealment (selection bias) Low risk Third-party randomisation was used, thus
we considered allocation concealment is
likely to have been done
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Moriarty 1999 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Marched placebos were taken
throughout to maintain the blinding of the
study (double-dummy technique)”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11 people left the study early and were not
included in the final analysis. Although the
dropout ratewasmarginally > 10%, it is un-
likely to have had a biased effect on the re-
sults, as reasons and proportion for dropout
were given and comparable between groups
Selective reporting (reporting bias) Low risk None obvious
Other bias High risk 1 of the study authors is an employee of
Napp Laboratories Ltd, a pharmaceutical
company that produces analgesics
Sample size small, 100 participants in total
in the 2 arms
Yu 2014
Methods Allocation: randomised
Blindness: double-blind
Duration: 3-phase study: screening period up to 14 days prior to randomisation; dose
titration phase up to 8 days, and a 28-day dose maintenance phase
Funding: not stated
Setting: China. Unclear if these are inpatients or community patients
Design: parallel
Participants Diagnosis: Chinese people with moderate to severe cancer pain
n = 260
Age: 18 to 70 years
Sex: men and women
History: most common of primary malignancies presented by people were lung, breast,
gastrointestinal and genitourinary
Included: people who required or were expected to require between 40 mg and 184 mg
of oral morphine or morphine equivalents every 24 hours for chronic management of
cancer pain and people who were reasonably expected to achieve a stable dose of opioid
study medication during the study
Exclusion: people with pure neuropathic pain or pain of unknown origin (where a
mechanism or physical cause could not be identified), only had pain on movement or
acute pain, required other opioid analgesics (apart from the morphine hydrochloride, in
IR formulation, allowed as rescuemedication for break through pain), had any significant
central nervous system disorder, risk of treatment with study medication could outweigh
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Yu 2014 (Continued)
the potential benefits, women of childbearing potential who were pregnant or lactating
Consent: written informed consent was obtained before entering the study
Interventions • Hydromorphone ER (OROS hydromorphone) 8 mg to 32 mg. n = 130
• Oxycodone CR 10 mg to 40 mg. n = 130
Study completed a dose titration phase (up to 8 days), and a 28-day dose maintenance
phase
Dose titration phase: randomised participants were converted from their prior opioids
to their morphine equivalents and titrated to adequate effect (as determined by the pain
assessments and supplementary analgesic requirements), and dosage adjustments were
made no more frequently than every 2 days. Upward and downward dose titrations were
allowed, but the maximum total daily dose was not to exceed hydromorphone ER 32
mg or oxycodone CR 80 mg
Participants had to achieve a stable dose providing pain control at least in the last 2 days
of the titration phase (2 to 8 days) to be eligible to enter the maintenance phase
Maintenance phase: the titrated dose was continued for 28 consecutive days. Upward
and downward dose titrations were not to exceed a total daily dose of hydromorphone
ER 32 mg or oxycodone CR 80 mg
Outcomes BPI pain intensity
Participant assessment of pain at its worst in the past 24 hours (assessed with BPI)
Pain at its least in the past 24 hours
Pain relief in the past 24 hours
Adverse events, assessed with treatment-emergent adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Central randomisation (1:1) by
an online dynamicminimization allocation
programme as the stratification factors was
implemented”
Comment: third-party central randomisa-
tion was used, thus is likely to be low risk
of bias
Allocation concealment (selection bias) Low risk Quote: “Interactivewebbased response sys-
tem designated a unique patient number
and treatment code, which dictated the
treatment assignment for each patient”
Comment: judging from the above descrip-
tion, allocation was concealed by the third
party who conducted randomisation
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Yu 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Hydromorphone ER, oxycodone
CR and placebo were provided in the form
of over-encapsulated tablets. Dosing had to
start in the morning and the study drug
was administrated twice daily, with placebo
tablet substitute for 1 dose of hydromor-
phone ER tomaintain blinding. The blind-
ing was broken only if specific emergency
treatment dictated knowing the treatment
status”
Comment: placebo was employed to mask
blinding where necessary, thus is likely to
be low risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 137/260 participants completed the study,
loss to follow-up > 10%
Selective reporting (reporting bias) Low risk It appears all measured outcomes were re-
ported
Other bias Unclear risk 50 to 199 participants per treatment arm
BPI: Brief pain inventory; CR: controlled release; ER: extended release; IR: instant release; n: number of participants; OROS: osmotic-
controlled release oral delivery system; SD: standard deviation; SR: slow release; VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Han 2014 Not a randomised controlled study.
Lee 2012 Not a randomised controlled study.
Wirz 2008 Not a randomised controlled study. Participants who were already taking the experimental and control medication were
randomly selected to be consented to take part in the study
Wirz 2009 Not a randomised controlled study. Participants who were already taking the experimental and control medication were
randomly selected to be consented to take part in the study
33Hydromorphone for cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of ongoing studies [ordered by study ID]
NCT02084355
Trial name or title Study Efficacy and Safety of Opioid Rotation Compared with Opioid Dose Escalation in Patients with
Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: open label
Primary purpose: supportive care
Participants People with cancer pain
Inclusion criteria: aged > 18 years; being treated with 1 strong opioid including oral oxycodone, oral
hydromorphone or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose;
moderate to severe cancer pain (numeric rating scale > 3) at screening; uncontrolled adverse effects associated
with currently applied opioid
Exclusion criteria: previous opioid rotation; unable to take oral medication; life expectancy < 1 month;
newly started chemotherapy or radiotherapy (or both) within past 2 weeks of screening; serum aspartate
aminotransferase, alanine aminotransferase, or alkaline phosphatase > 2.5 times of upper normal limit; serum
total bilirubin or creatinine > 1.5 times of upper normal limit
Interventions Oral oxycodone
Oral hydromorphone
Fentanyl patch
Outcomes Not described in the registration record.
Starting date April 2014
Contact information Se-Il Go; Tel: +82 55 750 9454 ext 9454; Email: gose1@hanmail.net
Notes Estimated completion date: January 2016
34Hydromorphone for cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Hydromorphone versus oxycodone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant-reported pain
intensity (skewed data)
Other data No numeric data
1.1 Visual analogue scale
(VAS) endpoint pain intensity
score (high score = poor
outcome)
Other data No numeric data
1.2 Brief Pain Inventory worst
pain in past 24 hours (change
score)
Other data No numeric data
2 Adverse event: measured with
VAS (high score = poor
outcome, skewed data)
Other data No numeric data
2.1 Nausea Other data No numeric data
2.2 Sedation Other data No numeric data
3 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Constipation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Leaving the study early 2 304 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.20, 1.87]
5 Death 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Hydromorphone versus morphine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participant-reported pain
intensity: Brief Pain Inventory
endpoint (slow-release phase)
subscale score (high = more
pain; data skewed)
Other data No numeric data
1.1 Worst pain subscale score Other data No numeric data
1.2 Least pain subscale score Other data No numeric data
1.3 Mean pain Other data No numeric data
2 Adverse events 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Confusion 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Headache 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Insomnia 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Nausea 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Pyrexia 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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3 Leaving the study early 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Overall 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Due to adverse events 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Due to lack of efficacy 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Death 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. Comparison 1: hydromorphone versus oxycodone (adverse events)
Adverse event Hydromorphone Morphine
No of reports Total (n) No of reports Total (n)
Abdominal discomfort 4 128 7 126
Abdominal distension 7 128 7 126
Anaemia 14 128 14 126
Asthenia 11 128 9 126
Bone marrow failure 9 128 9 126
Chest discomfort 9 128 6 126
Decreased appetite 20 128 21 126
Diarrhoea 12 128 9 126
Dizziness 21 128 22 126
Hyperhidrosis 3 128 8 126
Hypoproteinaemia 9 128 5 126
Neutrophil count de-
creased
7 128 5 126
Oedema peripheral 11 128 6 126
Platelet count decreased 8 128 7 126
Pyrexia 24 128 27 126
Rash 7 128 4 126
Urinary tract infection 4 128 7 126
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Table 1. Comparison 1: hydromorphone versus oxycodone (adverse events) (Continued)
White blood cell count
decreased
13 128 17 126
n: number of participants
Table 2. Comparison 2: hydromorphone versus morphine (adverse events)
Adverse event Hydromorphone Morphine
No of reports Treatment related No of reports Treatment related
Abdominal discomfort/
pain
2 1 5 1
Confusion 1 1 1 0
Constipation 1 1 2 1
Dizziness 2 2 2 2
Drowsiness 0 0 2 2
Fatigue 0 0 1 1
Nausea 3 2 2 0
Vomiting 3 1 2 0
Others 22 0 38 0
TOTAL 33 8 55 7
C O N T R I B U T I O N S O F A U T H O R S
Protocol development: all authors contributed equally.
Study screening: YJB, BJH.
Data extraction: YJB, BJH.
Data analysis: WH, XYK, LPY.
Report writing: YJB, BJH, JX, RK.
Future update: all authors in the existing team will be responsible for future updates.
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D E C L A R A T I O N S O F I N T E R E S T
YJB: none known; YJB is a specialist oncology physician and manages patients with cancer pain.
WH: none known; WH is a specialist oncology physician and manages patients with cancer pain.
XYK: none known; XYK is a pharmacologist.
LPY: none known; LPY is a specialist nephropathy physician and manages patients with nephropathy.
JX: none known; JX is a methodologist and does not have a clinical connection.
BJH: none known; BJH is a specialist oncology physician and manages patients with cancer pain.
RK: none known; RK is a pharmacist and manages patients with pain.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In accordance with the new Cochrane guidelines, we have used GRADE to assess the quality of evidence and added the method for
using GRADE to the review. We expanded the ’Description of the intervention’ section.
N O T E S
This review replaces the original review ’Hydromorphone for acute and chronic pain’ as the original author team were unavailable to
complete the update (Quigley 2013). The new review focuses on cancer pain only and adheres to current Cochrane standards.
I N D E X T E R M S
38Hydromorphone for cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Medical Subject Headings (MeSH)
Analgesics, Opioid [adverse effects; ∗therapeutic use]; Hydromorphone [adverse effects; ∗therapeutic use]; Morphine [adverse effects;
therapeutic use]; Neoplasms [∗complications]; Oxycodone [adverse effects; therapeutic use]; Pain [∗drug therapy; etiology]; Pain
Measurement; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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